Evidence map›Paper›PMID 31092690›Full record

ArticleJournal of lipid research2019

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.

Bastian Ramms, Sohan Patel, Chelsea Nora, Ariane R Pessentheiner, Max W Chang, Courtney R Green, Gregory J Golden, Patrick Secrest, Ronald M Krauss, Christian M Metallo and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Apolipoprotein C3: form begets function.Journal of lipid research · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Addressing dyslipidemic risk beyond LDL-cholesterol.The Journal of clinical investigation · 2022
    Review
  18. Article
  19. Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Bastian RammsDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Sohan PatelMedicine, University of California, San Diego, La Jolla, CA.
Chelsea NoraMedicine, University of California, San Diego, La Jolla, CA.
Ariane R PessentheinerMedicine, University of California, San Diego, La Jolla, CA.
Max W ChangDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Courtney R GreenBioengineering, University of California, San Diego, La Jolla, CA.
Gregory J GoldenDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Patrick SecrestDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Ronald M KraussChildren's Hospital Oakland Research Institute Oakland, CA.
Christian M MetalloBioengineering, University of California, San Diego, La Jolla, CA.
Christopher BennerDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Veronica J AlexanderIonis Pharmaceuticals Inc., Carlsbad, CA.
Joseph L WitztumMedicine, University of California, San Diego, La Jolla, CA.
Sotirios TsimikasMedicine, University of California, San Diego, La Jolla, CA.
Jeffrey D EskoDepartments of Cellular and Molecular Medicine,University of California, San Diego, La Jolla, CA.
Philip L S M GordtsMedicine, University of California, San Diego, La Jolla, CA pgordts@ucsd.edu.
University of California, San Diego · USLa Jolla Bioengineering Institute · USBielefeld University · DEIonis Pharmaceuticals (United States) · US

Funding

Siglec Modulation of Inflammatory ResponsesP01HL107150 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LE, DZUNG T · 2011 to 2017
$18.0M
LIPID METABOLISM IN ANIMAL CELLSR01GM033063 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ESKO, JEFFREY D · 1985 to 2019
$3.4M
Austrian Science Fund FWF J 4031NHLBI NIH HHS P01 HL107150NIGMS NIH HHS R01 GM033063
6 · The paper itself

Abstract

Hypertriglyceridemia results from accumulation of triglyceride (TG)-rich lipoproteins (TRLs) in the circulation and is associated with increased CVD risk. ApoC-III is an apolipoprotein on TRLs and a prominent negative regulator of TG catabolism. We recently established that in vivo apoC-III predominantly inhibits LDL receptor-mediated and LDL receptor-related protein 1-mediated hepatic TRL clearance and that apoC-III-enriched TRLs are preferentially cleared by syndecan-1 (SDC1). In this study, we determined the impact of apoE, a common ligand for all three receptors, on apoC-III metabolism using apoC-III antisense oligonucleotide (ASO) treatment in mice lacking apoE and functional SDC1 (

Indexed as

AnimalsApolipoprotein C-IIIApolipoproteins ELipoprotein LipaseMiceMice, Knockout, ApoEReceptors, LDLTriglyceridesApolipoprotein C-IIIApolipoproteins ELipoprotein LipaseReceptors, LDLTriglyceridesapolipoprotein C-IIIapolipoprotein Efatty acidslipaselipid metabolismlipoprotein lipasetriglyceride-rich lipoprotein clearance

Identifiers

PMID31092690
PMCPMC6672034
OpenAlexW2945419995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.